Telix Historical Income Statement

TLX Stock

15.76 0.16 1.03%

Historical analysis of Telix Pharmaceuticals income statement accounts such as Selling And Marketing Expenses of 57.6 M, Total Revenue of 521.5 M, Gross Profit of 323.9 M or Other Operating Expenses of 249.1 M can show how well Telix Pharmaceuticals Limited performed in making a profits. Evaluating Telix Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Telix Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Telix Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Telix Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About Telix Income Statement Analysis

Telix Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Telix Pharmaceuticals shareholders. The income statement also shows Telix investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Telix Pharmaceuticals Income Statement Chart

At this time, Telix Pharmaceuticals' Net Income is fairly stable compared to the past year.

Tax Provision Interest Income Depreciation And Amortization Selling General Administrative Selling And Marketing Expenses Net Income From Continuing Ops

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Most accounts from Telix Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Telix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At this time, Telix Pharmaceuticals' Net Income is fairly stable compared to the past year.

	2021	2023	2024 (projected)
Depreciation And Amortization	236.6K	6.7M	7.1M
Interest Income	1K	1.0M	1.1M

Depreciation And Amortization Interest Income

Telix Pharmaceuticals income statement Correlations

	Tax Provision	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense
Tax Provision		-0.41	-0.05	0.02	0.45	0.7	0.22	0.22	0.21	0.41	-0.45	-0.62	-0.48	0.32	-0.44	0.23	0.49	0.26	-0.56	-0.34	-0.62	1.0
Net Interest Income	-0.41		-0.88	-0.91	-0.95	-0.91	-0.97	-0.96	-0.96	-0.92	-0.6	-0.43	-0.58	-0.92	-0.61	-0.96	-0.94	-0.97	-0.49	0.99	-0.43	-0.41
Interest Income	-0.05	-0.88		1.0	0.78	0.65	0.97	0.96	0.97	0.8	0.91	0.8	0.9	0.83	0.91	0.96	0.78	0.92	0.84	-0.89	0.8	-0.05
Depreciation And Amortization	0.02	-0.91	1.0		0.82	0.7	0.98	0.98	0.98	0.83	0.88	0.76	0.86	0.85	0.88	0.97	0.81	0.94	0.8	-0.92	0.76	0.02
Interest Expense	0.45	-0.95	0.78	0.82		0.93	0.89	0.87	0.87	0.98	0.51	0.33	0.48	0.98	0.51	0.88	0.99	0.97	0.39	-0.94	0.33	0.45
Selling General Administrative	0.7	-0.91	0.65	0.7	0.93		0.82	0.82	0.82	0.93	0.3	0.1	0.27	0.89	0.31	0.83	0.96	0.87	0.17	-0.86	0.1	0.7
Selling And Marketing Expenses	0.22	-0.97	0.97	0.98	0.89	0.82		1.0	1.0	0.89	0.77	0.62	0.75	0.9	0.78	1.0	0.89	0.97	0.67	-0.96	0.62	0.22
Total Revenue	0.22	-0.96	0.96	0.98	0.87	0.82	1.0		1.0	0.89	0.77	0.63	0.75	0.89	0.78	1.0	0.89	0.96	0.68	-0.94	0.63	0.22
Gross Profit	0.21	-0.96	0.97	0.98	0.87	0.82	1.0	1.0		0.89	0.78	0.63	0.76	0.89	0.78	1.0	0.89	0.96	0.68	-0.94	0.63	0.21
Other Operating Expenses	0.41	-0.92	0.8	0.83	0.98	0.93	0.89	0.89	0.89		0.55	0.39	0.53	0.99	0.56	0.89	0.99	0.97	0.45	-0.9	0.39	0.41
Operating Income	-0.45	-0.6	0.91	0.88	0.51	0.3	0.77	0.77	0.78	0.55		0.98	1.0	0.61	1.0	0.77	0.5	0.7	0.99	-0.63	0.98	-0.45
Net Income From Continuing Ops	-0.62	-0.43	0.8	0.76	0.33	0.1	0.62	0.63	0.63	0.39	0.98		0.98	0.46	0.98	0.62	0.32	0.55	1.0	-0.47	1.0	-0.62
Ebit	-0.48	-0.58	0.9	0.86	0.48	0.27	0.75	0.75	0.76	0.53	1.0	0.98		0.59	1.0	0.75	0.47	0.68	0.99	-0.61	0.98	-0.48
Research Development	0.32	-0.92	0.83	0.85	0.98	0.89	0.9	0.89	0.89	0.99	0.61	0.46	0.59		0.62	0.9	0.98	0.98	0.51	-0.9	0.46	0.32
Ebitda	-0.44	-0.61	0.91	0.88	0.51	0.31	0.78	0.78	0.78	0.56	1.0	0.98	1.0	0.62		0.77	0.51	0.71	0.99	-0.64	0.98	-0.44
Cost Of Revenue	0.23	-0.96	0.96	0.97	0.88	0.83	1.0	1.0	1.0	0.89	0.77	0.62	0.75	0.9	0.77		0.89	0.96	0.67	-0.94	0.62	0.23
Total Operating Expenses	0.49	-0.94	0.78	0.81	0.99	0.96	0.89	0.89	0.89	0.99	0.5	0.32	0.47	0.98	0.51	0.89		0.96	0.38	-0.91	0.32	0.49
Reconciled Depreciation	0.26	-0.97	0.92	0.94	0.97	0.87	0.97	0.96	0.96	0.97	0.7	0.55	0.68	0.98	0.71	0.96	0.96		0.61	-0.96	0.55	0.26
Income Before Tax	-0.56	-0.49	0.84	0.8	0.39	0.17	0.67	0.68	0.68	0.45	0.99	1.0	0.99	0.51	0.99	0.67	0.38	0.61		-0.52	1.0	-0.56
Total Other Income Expense Net	-0.34	0.99	-0.89	-0.92	-0.94	-0.86	-0.96	-0.94	-0.94	-0.9	-0.63	-0.47	-0.61	-0.9	-0.64	-0.94	-0.91	-0.96	-0.52		-0.47	-0.34
Net Income	-0.62	-0.43	0.8	0.76	0.33	0.1	0.62	0.63	0.63	0.39	0.98	1.0	0.98	0.46	0.98	0.62	0.32	0.55	1.0	-0.47		-0.62
Income Tax Expense	1.0	-0.41	-0.05	0.02	0.45	0.7	0.22	0.22	0.21	0.41	-0.45	-0.62	-0.48	0.32	-0.44	0.23	0.49	0.26	-0.56	-0.34	-0.62

Click cells to compare fundamentals

Telix Pharmaceuticals Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Telix Historical Income Statement

About Telix Income Statement Analysis

Telix Pharmaceuticals Income Statement Chart

Tax Provision

Interest Income

Depreciation And Amortization

Telix Pharmaceuticals income statement Correlations

Telix Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Telix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Income Tax Expense	+ 1.0	Tax Provision
Depreciation And Amortization	+ 1.0	Interest Income
Total Revenue	+ 1.0	Selling And Marketing Expenses
Gross Profit	+ 1.0	Selling And Marketing Expenses
Cost Of Revenue	+ 1.0	Selling And Marketing Expenses
Gross Profit	+ 1.0	Total Revenue

Reconciled Depreciation	- 0.97	Net Interest Income
Selling And Marketing Expenses	- 0.97	Net Interest Income
Total Other Income Expense Net	- 0.96	Reconciled Depreciation
Total Other Income Expense Net	- 0.96	Selling And Marketing Expenses
Cost Of Revenue	- 0.96	Net Interest Income
Gross Profit	- 0.96	Net Interest Income